Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 16 of 28 for:    sickle cell | "Sickle Cell Trait"

DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry (DREPAMASSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03985501
Recruitment Status : Not yet recruiting
First Posted : June 13, 2019
Last Update Posted : June 13, 2019
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:

Three methods are actually used in newborn screening for sickle cell disease (SCD) in France: isoelectric focusing, high performance liquid chromatography and capillary electrophoresis. New technologies are currently under development such as Matrix Assisted Laser Desorption Ionisation - Time of Flight (MALDI-TOF) and tandem mass spectrometry (MS/MS) using the SpOtOn Diagnostics Reagent Kit available in United Kingdom only.

Zentech company (Liège, Belgium) is developing a package for SCD newborn screening using MS/MS technology. The main objective of the present study will be to compare this new technique with the technique actually used in the hospital center of Lille (sub-contractor for SCD newborn screening of Lyon) and the haemoglobin analysis to test its accuracy (sensitivity and specificity).


Condition or disease Intervention/treatment
Sickle Cell Disease Infant, Newborn, Disease Drepanocytosis Other: SCD newborn screening with the MS/MS method from Zentech

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1040 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: DREPAMASSE Study - Evaluation of a Newborn Screening for Sickle Cell Disease by Tandem Mass Spectrometry
Estimated Study Start Date : September 1, 2019
Estimated Primary Completion Date : September 1, 2020
Estimated Study Completion Date : September 1, 2020

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
newborn screening for sickle cell disease
Newborns with a targeted neonatal screening for sickle cell disease carried out at the University Hospital of Lyon
Other: SCD newborn screening with the MS/MS method from Zentech
The analysis of the SCD newborn screening with the MS/MS method from Zentech will be realized after achievement and biological validation of the SCD newborn screening in the usual care pathway. The results will be compared with the method used at the Lille Academic Hospital (CHU Lille) (sub-contractor for SCD newborn screening of Lyon)




Primary Outcome Measures :
  1. Percent agreement between the two techniques [ Time Frame: 6 months ]
    Non-inferiority (difference <1%) in terms of sensitivity and specificity between the results obtained with the MS/MS method and those obtained with the technique currently used at the Lille CHU (sub-contractor for SCD newborn screening of Lyon)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 27 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Infants with SCD newborn screening conducted in the hospital center of Lyon
Criteria

Inclusion Criteria:

  • Infants with SCD newborn screening conducted in the hospital center of Lyon

Exclusion Criteria:

  • Insufficient quantity of sampling
  • Parents' opposition to their newborn's participation in the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985501


Contacts
Layout table for location contacts
Contact: Dr Céline RENOUX, MD, PhD 04.27.85.65.94 ext +33 celine.renoux@chu-lyon.fr
Contact: David CHEILLAN, MD, PhD 04 72 12 96 88 ext +33 david.cheillan@chu-lyon.fr

Locations
Layout table for location information
France
Groupement Hospitalier Est - Hospices Civils de Lyon Not yet recruiting
Bron, France, 69677
Contact: Céline RENOUX, MD, PhD    04.27.85.65.94 ext +33    celine.renoux@chu-lyon.fr   
Contact: David CHEILLAN, MD, PhD    04 72 12 96 88 ext +33    david.cheillan@chu-lyon.fr   
Principal Investigator: Céline RENOUX, MD, PhD         
Principal Investigator: Muriel DORET-DION, MD, PhD         
Principal Investigator: Olivier CLARIS, PU, PH         
Hôpital de la Croix Rousse Not yet recruiting
Lyon, France, 69317
Contact: Cyril HUISSOUD, PU, PH         
Contact: Jean-Charles PICAUD, PU, PH         
Principal Investigator: Cyril HUISSOUD, PU, PH         
Principal Investigator: Jean-Charles PICAUD, PU, PH         
Centre Hospitalier Lyon Sud Not yet recruiting
Pierre-Bénite, France, 69495
Contact: François GOLFIER, PU, PH         
Principal Investigator: François GOLFIER, PU, PH         
Sponsors and Collaborators
Hospices Civils de Lyon

Layout table for additonal information
Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT03985501     History of Changes
Other Study ID Numbers: 69HCL19_0338
2019-A01346-51 ( Other Identifier: ID-RCB )
First Posted: June 13, 2019    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Infant, Newborn, Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn